Eckert & Ziegler and GlyTherix have extended their existing lutetium-177-based collaboration with a global supply agreement for actinium-225 (Ac-225).
Under the terms of the deal, Eckert & Ziegler will provide Ac-225 to GlyTherix for its clinical research and development activities on alpha radiotherapeutics. GlyTherix’s radiotherapy approach combines a radionuclide with an antibody targeting Glypican-1, a protein found in aggressive cancers, to deliver localized radiation while sparing healthy tissue, Eckert & Ziegler said.
In December 2024, Eckert & Ziegler started production of Ac-225 as part of a collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (ÚJF), it noted.